Monday AM report 05-10-10.

Slides:



Advertisements
Similar presentations
NOSOCOMIAL ANTIBIOTIC RESISTANT ORGANISMS
Advertisements

Gastrointestinal Problems Claire Nowlan MD. Peptic Ulcers Ulceration of either the gastric or duodenal mucosa.
Photomicrograph courtesy of SL Gorbach C. difficile Screening and Identification Fact or Fiction Lisa E Davidson, MD Tufts Medical Center Boston, MA.
Relapsing and Severe C. difficile Disease Role of Fecal Microbiota Transfer.
SUBHAJIT SARKAR ASSISTANT PROFESSOR UNM DEPARTMENT OF MEDICINE SECTION OF HOSPITAL MEDICINE AUGUST 2010 Clostridium difficile update Recent Treatment.
Jayesh Patel, MD, DTM&H Infectious Disease Consultant Chair Infection Prevention and Pharmacy/Therapeutics/Nutrition (Skyline)
Clostridium Difficile Infectious Diarrhea
CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA VALERIE FLETCHER, M.D. INFECTIOUS DISEASES SOUTHERN OHIO MEDICAL CENTER August 2006.
Neil Stollman MD, FACP, FACG Associate Clinical Professor of Medicine
Clostridium Difficile
Clostridium difficile Presented by Nate Smith, MD, MPH Carole Yeung, RN CIC.
Clostridium Difficile (C.diff): Fast Facts. What is Clostridium difficile (C. diff)? C. diff is a bacteria that lives in the intestinal tract of about.
Antimicrobial Resistance in Hospitals: Lack of Effective Treatment for Gram Negative Bacilli and the Rise of Resistant Clostridium difficile Infections.
Deadly Diarrhea …and the salvation of stool Teri Brentnall, M.D. Professor, Medicine Gastroenterology.
Microbe of the Week Mycobacterium marinum The aquarium or fish tank disease,first reported in 1962 Rare but important if not treated Living example-Karen.
Katelyn R Richards, PharmD
C. Difficile and Fecal Microbiota Therapy
Ulcerative Colitis.
Clostridium difficile Colitis. C. diff.—Gram stain.
New CLOSTRIDIUM DIFFICILE CDI Prevention Bundles
Clostridial infections *C.difficile is found as a part the normal bowel flora in 3-5% of the pooulation and even more commonly in hospitalized patients.
Management of Clostridium difficile Infections
Progress in Diagnosing and Treating Clostridium difficile in IBD patients Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine Director of.
1 What’s All the Fuss About Clostridium difficile? Peter C. Iwen, PhD, D(ABMM) Nebraska Public Health Laboratory
Antimicrobials and risks for antibiotic-associated diarrhea (AAD) Antibiotic-associated diarrhea 5-30% risk Higher with multiple IV drugs Higher with broad.
Probiotics Terms: Probiotic – Probiotics are live microorganisms (bacteria or yeasts) which, when administered in adequate amounts, confer a health benefit.
MICR 420 Emerging and Re-Emerging Infectious Diseases Lecture 4: C. difficile Dr. Nancy McQueen & Dr. Edith Porter.
Microbiology Nuts & Bolts Test Yourself - Gastrointestinal Begin here.
Clostridium difficile Infections: Diagnosis, Treatment, and Prevention Theresa Cuoco, MD.
Dalia Munoz.  Its an inflammatory bowel disease (IBD) that causes a long- lasting inflammation in your digestive tract.
Big Bad Bugs in the Dialysis Unit Douglas Shemin, MD Kidney Diseases and Hypertension Division, Rhode Island Hospital.
Clostridium difficile Prevention and Treatment Katrina Beining & Christina Gardner Introduction Clostridium difficile (C. diff) is a gram-positive, spore-forming.
What’s All the Fuss About Clostridium difficile? Peter C. Iwen, PhD, D(ABMM) Nebraska Public Health Laboratory.
Gastrointestinal Problems Claire Nowlan MD Jan 16, 2004.
“Don’t Drink the Water”: A Primer on Infectious Diarrhea Patty W. Wright, MD with appreciation to Ban Allos, MD March 2011.
Clostridium Difficile: Epidemiology and Clinical Spectrum Cassandra D Salgado, MD, MS Associate Professor of Medicine Hospital Epidemiologist, MUSC March.
Outline C. difficile infection Fecal microbiota
Ulcerative colitis.
Confirmed cases: Deaths:. Villain NOT superhero…..
October 2, 2014 For the Georgia Hospital Association(GHA)/
Preventing and Treating C.difficile Lisa Casey, M.D. Assistant Professor, UT Southwestern Medical Center TSGE / SGNA Annual Scientific Meeting September.
 Total or segmental nonobstructive colonic dilatation  PLUS systemic toxicity  Most commonly transverse colon.
Case Presentation Thamer Abdullah Bin Traiki. Case Presentation A 44-year-old woman with a history of multiple complicated urinary tract infections requiring.
NYU Medical Grand Rounds Clinical Vignette Andy Levy, MD PGY-2 March 26, 2013 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
It's Time A 63-year-old woman was admitted because of severe abdominal pain, fatigue and bloody diarrhea.
Clostridium difficile
Clostridium difficile Separating key facts from fiction S P Borriello
Clostridium Difficile BY: KELSEY COMBS AND ROSA CORDOVA.
Lec. No. 11 Dr. Manahil Clostridium difficile C. difficile is a gram positive, spore forming, obligate anaerobe. Colonies of the organism are about 4mm.
Clostridium difficile Ricardo A. Caicedo, M.D.. OBJECTIVES Introduction Epidemiology Clinical spectrum Diagnosis Treatment Prevention.
Clostridium Difficile Infection:
Clostridium difficile infections
Clostridium difficile infection (CDI) 소화기내과 R4 신아리 1.
Complications in IBD for acute internal medicine S Sebastian.
JAMA Internal Medicine May 2015 Volume 175, Number5 R1 조한샘 / Prof. 이창균.
Clostridium difficile Infection Fellow 이시내. Clostridium difficile  An anaerobic gram-positive, spore-forming, toxin-producing bacillus.  Transmitted.
Nosocomial Antibiotic Resistant Organisms
A gastrointestinal problem
Clostridium Difficile Patients In the Endoscopy Center
and brain injured patients in an inpatient rehabilitation hospital
NOSOCOMIAL ANTIBIOTIC RESISTANT ORGANISMS
Improvement of management and reduction in mortality following implementation of audit recommendations in Clostridium difficile diarrhoea at James Cook.
Antimicrobial Resistance in Hospitals: Lack of Effective Treatment for Gram Negative Bacilli and the Rise of Resistant Clostridium difficile Infections.
Management of Clostridium Difficile Infection
Clostridium difficile
Clostridium Difficile Infectious Diarrhea
Clostridium difficile Update
CLINICAL SOLVING PROBLEM
C. difficile Update Kim Vermedal, RN, MSN, CIC APIC January 25, 2019.
Current Threats to Public Health
Presentation transcript:

Monday AM report 05-10-10

Clostridium difficile infection

Introduction Clostridium difficile is an anaerobic gram-positive, spore-forming toxin-producing bacillus. Toxin A directly activates Neutrophils. Toxin B mediates colonic mucosal damage. Cardinal symptom is watery diarrhea up to 10-15 per day, abdominal pain, leukocytosis, low grade fever. Nr. 1 reason for unexplained leukocytosis in hospitalized pts. Even w/o diarrhea!!! Hypervirulent strain NAP1/BI/027 produces larger quantities of toxins.

Epidemiology Clostridium difficile associated disease (CDAD) is one of the most common hospital-acquired (nosocomial) infections. Infections doubled to 61/100000 between 1996 and 2003. 20-50% of hospitalized pts. and long term care pts. are carriers. 3% of healthy individuals. Risk factors: Antibiotic use, hospitalization, advanced age, PPIs, severe illness, enteral feeding, gastrointestinal surgery, chemo.

Assessment Initial step is cessation of the inciting antibiotic (mostly PCN, fluoroquinolones, cephalosporines and clindamycin) Switch to aminoglycosides, tetracyclines, chloramphenicol, metronidazol or vancomycin if pt. requires Abx treatment. Contact precautions and wash hands with soap and water. Severe or non-severe disease? No Consensus definition! WBC >20.000 cells/ml, Temp > 38.3*C, Albumin<2.5mg/dl, Age > 60 (each 1 point), 2 points for endoscopic evidence of pseudomembranous colitis or treatment in ICU. -> Severe disease = 2 or more points!

Treatment of initial episode Preferred: Metronidazole 500mg po tid or 250mg qid for 10-14 days. IV only if pt. with n/v. Alternative: Vancomycin 125mg po qid for 10-14 days.

Therapy for relapse 50% are reinfections rather than relapses and mostly occur within 1-2 weeks (up to 2-3 months) after Abx discontinuation. Since a positive stool toxin assay does not exclude asymptomatic carriage, other causes (infections, IBD, IBS) have to be investigated. Mild symptoms can be managed conservatively If Abx are needed repeat treatment of initial episode.

Second relapse Exclude other causes!!! Tapering and pulsed oral vancomycin: - 125mg po qid for 7 days - 125mg po bid for 7 days - 125mg po qd for 7 days - 125mg po q48h for 7 days - 125mg po q72h for 7 days A three week course of probiotics (eg, Saccharomyces boulardii 500mg bid) may be used.

Subsequent relapse Exclude other causes!!! Vancomycin 125mg po qid for 14 days followed by Rifaximin 400mg bid for 14 days.

Severe disease WBC >20.000 cells/ml, Temp > 38.3*C, Albumin <2.5mg/dl, Age > 60 (each 1 point), 2 points for endoscopic evidence of pseudomembranous colitis or treatment in ICU. -> Severe disease = 2 or more points! Watch out for toxic megacolon and perforation!!! (Call surgery) Metronidazole 500mg q8h IV!!! (cave: n/v) Vancomycin 500mg!!! Po qid + Vancomycin enemas (0.5-1g) q4h to q12h Treatment 10-14 days or if pt. on Abx for other diseases plus an additional week after discontinuation.

Pseudomembranous colitis

Thank you